Year 2024 / Volume 116 / Number 6
Original
Screening and risk of hepatocellular carcinoma in patients with advanced fibrosis after hepatitis C virus eradication

305-311

DOI: 10.17235/reed.2024.9945/2023

Silvia Espina Cadena, Diego Casas Deza, Belén Julián Gomara, Cristina Victoria Borao Laguna, Olivia Sierra Gabarda, Luis Javier Lamuela Calvo, Sara Lorente, Trinidad Serrano, José Miguel Arbonés Mainar, Vanesa Bernal Monterde,

Abstract
Introduction: the risk of hepatocellular carcinoma (HCC) after eradication of the hepatitis C virus (HCV) is highly variable in patients with advanced fibrosis (F3). Long-term surveillance for HCC after sustained virological response (SVR) is controversial in these patients. The objective of this study was to describe the post-SVR follow-up in clinical practice in patients with F3 and determine the predictive factors for the development of HCC. Patients and methods: a multicenter, observational and retrospective study was performed, which included HCV-monoinfected patients with F3 fibrosis determined by transient elastography who achieved SVR between 2015 and 2022, with follow-up until May 2023. Clinical-demographic, laboratory, elastography, and ultrasound variables were recorded before and after treatment. A descriptive and inferential analysis, Cox regression analysis and survival analysis were carried out with the R statistical software. Results: two hundred and nineteen patients were included in the study (65.3 % males, median age 57 years), and 175 (79.9 %) received ultrasound screening after SVR for 62 (6-90) months. The prescribing service was the only independent variable related to performing ultrasound surveillance (p = 0.004). Eight patients developed HCC. In multivariate analysis adjusted for sex, age, presence of diabetes and alcohol consumption, a post-SVR FIB-4 ≥ 3.25 was associated with a 12-fold increase in HCC risk. The cumulative probability of HCC was higher in the group of patients with FIB-4 ≥ 3.25 after SVR (p < 0.001). Conclusion: post-SVR follow-up of patients with F3 fibrosis is variable in clinical practice. Using the FIB-4 after SVR allows us to identify those patients with a higher risk of HCC who benefit from biannual ultrasound screening.
Lay Summary
The risk of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication in individuals with advanced fibrosis (F3) is variable. Therefore, risk factors that identify patients in whom HCC screening is cost-effective after sustained virological response (SVR) are currently being investigated. The objective of our study was to describe the follow-up after HCV eradication in patients with F3 stage and to determinate the predictive factors for the development of HCC. For this purpose, an observational, retrospective, and multicenter study was carried out with all the 8 reference hospitals of the autonomous community of Aragon, Spain. Patients with HCV and F3 fibrosis stage by vibration-controlled transient elastography treated with direct-acting antivirals (DAA) were included. Clinical-demographic, analytical, elastography and sonographic variables were collected, before and after antiviral treatment. A total of 219 patients were included, of which 79.9% received follow-up with biannual abdominal ultrasound after SVR. The only variable associated with surveillance was the service prescribing antiviral therapy. During follow-up, 8 patients developed HCC. In the multivariate analysis, the presence of a FIB-4 index ≥ 3.25 after DAA was associated with a 12-fold increased risk of HCC. Furthermore, in the survival analysis, the cumulative probability of HCC was higher in patients with a FIB-4 index ≥ 3.25 after treatment. Therefore, the use of this index during surveillance after SVR could be a tool to identify those individuals at higher risk of HCC.
Share Button
New comment
Comments
No comments for this article
Related articles

Editorial

Hemophilia and hepatology, back to the future

DOI: 10.17235/reed.2024.10105/2023

Digestive Diseases Image

Black esophagus

DOI: 10.17235/reed.2022.9217/2022

Digestive Diseases Image

Giant cystic hepatocarcinoma in the absence of cirrhosis

DOI: 10.17235/reed.2021.8313/2021

Original

Hepatitis C in homeless people: reaching a hard-to-reach population

DOI: 10.17235/reed.2021.7737/2020

Letter

Biopsy for hepatocellular carcinoma: only occasionally

DOI: 10.17235/reed.2020.6935/2020

Letter

Hepatocarcinoma diagnosis. Reflection is required

DOI: 10.17235/reed.2020.6845/2019

Letter

Rhabdomyolysis in a patient under treatment with sorafenib

DOI: 10.17235/reed.2020.6440/2019

Case Report

Ectopic hepatocellular carcinoma arising from the peritoneum

DOI: 10.17235/reed.2019.6408/2019

Editorial

Lung transplantation and esophageal dysfunction

DOI: 10.17235/reed.2018.5693/2018

Original

Colonic diverticulosis and the metabolic syndrome: an association?

DOI: 10.17235/reed.2017.5009/2017

Digestive Diseases Image

Debut of an unusual liver cirrhosis

Review

New challenges in clinical research on hepatocellular carcinoma

DOI: 10.17235/reed.2015.4012/2015

Citation tools
Espina Cadena S, Casas Deza D, Julián Gomara B, Borao Laguna C, Sierra Gabarda O, Lamuela Calvo L, et all. Screening and risk of hepatocellular carcinoma in patients with advanced fibrosis after hepatitis C virus eradication. 9945/2023


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1351 visits.
This article has been downloaded 122 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 07/09/2023

Accepted: 12/12/2023

Online First: 11/01/2024

Published: 04/06/2024

Article revision time: 80 days

Article Online First time: 126 days

Article editing time: 271 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology